China Increases its Activity in Regulated Markets
|
|
- Vernon Phillips
- 7 years ago
- Views:
Transcription
1 China Increases its Activity in Regulated Markets By Bob Kennedy, Thomson Reuters Traditionally China has been viewed as a low-cost provider of raw materials, chemical intermediates and offpatent active pharmaceutical ingredients (APIs) but China is moving up the global pharmaceutical supply chain and they are no longer just a low-cost threat. For example, Chinese companies are developing newer molecules, they are gaining experience through partnerships with major innovator and generic companies and a few have finished dosage presence within regulated markets. API Manufacturing Sector Early last year it was reported that the Chinese government planned to invest up to $750 million to build up capacity to produce APIs for drug makers in Western countries. According to figures developed by Thomson Reuters, the number of Chinese manufacturing groups capable of supplying APIs to regulated markets has steadily increased over the last six years (see figure 1). Source: Thomson Reuters Although more than 80% of the manufacturing groups in China today are rated as Local by Thomson Reuters meaning that they are neither interested in, nor capable of supplying API to regulated markets the number of Established and Less Established Chinese groups has grown considerably since However, the really dramatic increase has been among the Potential Future companies in China that are looking to enter regulated markets despite very limited or no known performance. Over time, a number of Chinese groups have made the progression to the Less Established and Established categories by making investments in their facilities and people and gaining the experience they previously lacked by working with regulated market players (see figure 2).
2 Of the 13 groups rated as Established in 2011, only two groups held the same rating in 2005 Zhejiang Hisun and Shandong Xinhua. A number of others, however, have moved up in the rankings. In 2005 two of those groups were rated as Less Established, five were rated as Potential Future, one was rated as Local and the remaining three groups were not rated. It is quite remarkable that over a span of just six years, 11 Chinese groups ascended to the top of the API manufacturer rating scheme from their initial ratings in Contributing to China s success as a global hub for API manufacturing are its talented pool of scientists and engineers, lower cost base than in regulated markets, better infrastructure in comparison to India and also an improving GMP and patent protection environment. There has been an increase in the number of regulatory filings by Chinese groups since 2000 and this certainly highlights China s desire to enter regulated markets (see figure 3).
3 Where China leads, and in some cases has overtaken India, is in classes of fermentation-based APIs, steroids, intermediates and many base chemicals. Given this fact, it is not surprising that Chinese companies have supply agreements for APIs and intermediates with both big pharma and generics (see table 1). The majority of these supply agreements are for older off-patent molecules but some Chinese companies are developing noninfringing processes for newer molecules years before patent expiry. Among them is Jiangsu Hansoh who manufactured the API in support of Hospira s US patent challenge for gemcitabine hydrochloride injection. Source: Thomson Reuters Finished Dose Presence Because the Chinese market is large and lucrative, most companies are building up capacity to serve the rapidly growing local market with finished dose. However, a number of companies are also expanding into finished dose markets outside of China. In order to gain access to regulated finished dose markets, Chinese companies are entering into partnerships with experienced Western players (see table 2). The majority of these deals are for future co-development of finished dosage forms but Shandong Xinhua, Zhejiang Hisun and Zhejiang Huahai are currently manufacturing finished dose for regulated markets. Other Chinese groups have publically expressed their aspirations to produce finished dosage forms for regulated markets but have yet to form a strategic partnership with an experienced Western company.
4 In the summer of 2011, two major joint ventures were announced between Pfizer/Hisun and Merck/Simcere for the production of branded generics in China. We expect that if these joint ventures are successful, the agreements could be extended to regulated markets in the future. And recently, Lilly expanded its strategic partnership with Novast to broaden its branded generic presence in China. The collaboration may also lead to Novast providing local and regional manufacturing capabilities for Lilly s pipeline of new drug candidates down the road. After waiting many years, Chinese abbreviated new drug applications (ANDAs) became a reality in the US market in December Currently, eight Chinese groups hold a combined 28 ANDAs with final US FDA approval (see table 3). Zhejinag Huahai and Novast lead the pack with nine approvals each. All of the current approvals are for oral dosage formulations with the exception of Jiangsu Hengrui and Zhejiang Hisun, who are the only Chinese companies who hold final US FDA approval for injectable products.
5 Interestingly, a few applicants filed their ANDAs under more Western-sounding names. Eight of the nine ANDAs belonging to Zhejiang Hauhai were transferred to their US subsidiary Prinston and China Resources Holdings received final US FDA approval for amlodipine besylate tablets via their US subsidiary Secan. Among the 28 Chinese ANDAs with US FDA approval, approximately half of these were acquired from generics firms with a US presence (Actavis, Par, Ranbaxy, etc). We believe that manufacturing for at least some of these ANDAs will be moved to China to take advantage of lower manufacturing costs but the current US FDA backlog will likely slow down that process. In addition to those ANDAs that were acquired, 5 Chinese groups hold final US FDA approval for ANDAs developed-in house. We believe that additional filings by Chinese companies are waiting for approval. Future Prospects Post-2015, the majority of small molecule products coming off-patent will be small-volume, high-value products within the specialist-driven oncology and orphan drug categories. The brand sales exposed to generic competition will decline dramatically starting in 2013, as a result of fewer blockbuster drugs losing patent protection. Going forward, future patent expiries will be for smaller and more specialized products and only those Chinese companies with strong technological capabilities in niche areas will be in an advantageous position to profit from this future opportunity. Chinese manufacturers looking to enter the lucrative small molecule oncology market will need to invest in high potency API manufacturing capabilities. This will require specialized equipment for containment, operator training and safety practices. Biologics are another form of specialized manufacturing and it is predicted that by 2016, 7 of the 10 top selling drugs will be biologics. Several Chinese companies have launched various recombinant proteins and vaccines in their domestic market and some, including Fosun, Jiangsu Hengrui and Shanghai Biomabs, are also pursuing development of monoclonal antibodies (see table 4).
6 Small and medium-sized companies account for the majority of the firms in China s pharmaceutical industry and many of these manufacturers currently have heavy debt burden and a lack of funds that will impede their ability to comply with the new set of Chinese good manufacturing practice (GMP) regulations that were implemented in March of Many smaller companies will, no doubt, be eliminated from the market. This phenomenon will result in the consolidation of China s manufacturing base, weeding out players with poor quality standards while advancing the competitiveness of the remaining companies in the international market. With drug manufacturing standards significantly raised, manufacturing costs will increase but so also will product quality. Over the next several years, China s government plans to assist some 60 manufacturers in the API sector with the goal of reaching international quality standards and boosting API exports to regulated markets. Furthermore, we expect that additional Chinese companies will develop newer molecules and pursue finished dose opportunities in regulated markets through partnerships with experienced Western players. Bob Kennedy is Manager of Industry Research at Thomson Reuters and is responsible for overseeing the activities of the research team who actively collect and validate the competitive API intelligence that is contained within the Newport product suite. Bob has published several articles, appearing in Scrip World Pharmaceutical News and Specialty Chemicals Magazine, analyzing China s evolving role in the global pharmaceutical industry. He can be reached at robert.kennedy@thomsonreuters.com.
STATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry
Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators
More informationFirst to File and Beyond: Paragraph IV Business Strategies
First to File and Beyond: Paragraph IV Business Strategies THOMSON REUTERS INTELLECTUAL PROPERTY & SCIENCE GENERICS & API INTELLIGENCE Benjamin Burck Research Analyst and Project Manager Generics & API
More informationSWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY
SWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY KAPIL KUMAR*; DR. M. K. KULSHRESHTHA** *RESEARCH SCHOLAR, BHAGWANT UNIVERSITY, AJMER ** DIRECTOR, S. D. COLLEGE OF MANAGEMENT, PANIPAT ABSTRACT The global
More informationAn integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
More informationBrand Quality with Asian Advantages
Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com
More informationGOVERNORS MEETING FOR HEALTHCARE INDUSTRIES. The Indian Opportunity in pharmaceutical R&D and manufacturing
WORLD ECONOMIC FORUM ANNUAL MEETING 2008 GOVERNORS MEETING FOR HEALTHCARE INDUSTRIES DAVOS - THURSDAY 24 JANUARY The n Opportunity in pharmaceutical R&D and manufacturing Prepared by Bain & Company Thursday,
More informationXarelto-API Insights. Brochure More information from http://www.researchandmarkets.com/reports/3043740/
Brochure More information from http://www.researchandmarkets.com/reports/3043740/ Xarelto-API Insights Description: Summary The active pharmaceutical ingredients worldwide market is in continuous development
More informationHealthcare. abc. Healthcare team
team Nam Park* Regional Head of Research, Asia Pacific The Hongkong and Shanghai Banking Corporation Limited +852 2996 6591 nampark@hsbc.com.hk Carolyn Poon* Analyst The Hongkong and Shanghai Banking Corporation
More informationMost countries will experience an increase in pharmaceutical spending per capita by 2018
6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationRecipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India
Press release 18 th April 2016 Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India Recipharm AB (publ) ( Recipharm or the Company ) announces
More informationChina Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results
China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully
More informationFurther Developments of Hong Kong s Offshore RMB Market: Opportunities and Challenges
Further Developments of Hong Kong s Offshore RMB Market: Opportunities and Challenges Zhang Ying, Senior Economist In recent years, as the internationalization of the RMB has been steadily carrying out,
More informationPromote Two-Way Flow of International Students, Improve Quality of International Students Education in China
Promote Two-Way Flow of International Students, Improve Quality of International Students Education in China Speech on the Sino-Australian Forum on Transnational Education and Student Mobility Ms TIAN
More informationDrug Regulations in India Dr. Surinder Singh Drugs Controller General (India) Meeting With Ambassadors / High Commissioners of African Countries 24
Drug Regulations in India Dr. Surinder Singh Drugs Controller General (India) Meeting With Ambassadors / High Commissioners of African Countries 24 th April 2009, New Delhi Flow of presentation About Indian
More informationThere is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz
There is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz Recently, we participated in a seminar on United States (US) Food and Drug Administration (FDA) regulations to the Hebei Pharmaceutical
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationAnnual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationJanuary 2016. Price Declines after Branded Medicines Lose Exclusivity in the U.S.
January 2016 Price Declines after Branded Medicines Lose Exclusivity in the U.S. Introduction When novel medicines lose exclusivity in the United States, competitors quickly enter the market and bring
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More informationDPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013.
DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013 Page Safe harbor statement This presentation may contain forward-looking
More informationPatent Expiry Impact Predictor
Patent Expiry Impact Predictor Compiled and written by Datamonitor plc Datamonitor plc (DTML) is a premium business information company specialising in industry analysis and providing clients with unbiased
More informationMultitude of opportunities for Finnish pharmaceutical industry in India
1 Multitude of opportunities for Finnish pharmaceutical industry in India Dr. Esa Heinonen, MD, PhD Senior Advisor Business Development and Support Orion Pharma 2 3 Challenges of pharmaceutical industry
More informationPfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off?
Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off? Research February 6, 2012 Rusty Jones Companies: Pfizer (PFE) Ranbaxy (OTC: RBXZF) Watson (WPI) Products: Lipitor
More informationWriting a Business Plan. Dr. Michael Entzeroth CSO/COO Cennerv Pharma (S) Pte Ltd, Singapore
Writing a Business Plan Dr. Michael Entzeroth CSO/COO Cennerv Pharma (S) Pte Ltd, Singapore Agenda Reasons for writing a business plan Business plan content Executive Summary The company: description and
More informationHow companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationThe Future of Consumer Health Care
The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More
More information(1) MAJOR TRANSACTION ACQUISITION OF FURTHER EQUITY INTERESTS IN SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD.; AND (2) CHANGE IN USE OF PROCEEDS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
More informationInternational Business Strategy
International Business Strategy Executive Summary The Canadian automotive industry, and in particular the automotive component parts industry is part of the broader global industry. Canadian suppliers
More informationPRESS RELEASE Noida, Tuesday, February 9, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q3 & 9M FY2016 RESULTS JUBILANT
More informationFlamel Technologies Provides Update on Corporate Progress
Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:
More informationSalary Survey 2014. Domestic, International Salary Survey and Country Cost Analysis
Salary Survey 2014 Domestic, International Salary Survey and Country Cost Analysis Disclaimer: This salary guides contained herewith have been constructed to represent average salaries across a range of
More informationThe 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
More informationTemple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034. Phone: 267.468.8560 Fax: 267.468.
Temple University - School of Pharmacy Phone: 267.468.8560 Fax: 267.468.8565 BACKGROUND POST-MASTER S CERTIFICATE in BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers the first specialized certificate
More informationMARKET FOCUS REPORT THE VALUE OF MOBILE AND SOCIAL FOR CRM
Document M13 MARKET FOCUS REPORT THE VALUE OF MOBILE AND SOCIAL FOR CRM THE BOTTOM LINE Adding mobile access and social collaboration to CRM delivers significant benefits. In a survey of CRM decision makers,
More informationXarelto-Drug Insights,2014
Brochure More information from http://www.researchandmarkets.com/reports/2977191/ Xarelto-Drug Insights,2014 Description: Xarelto - Drug Insights, 2014 provides Xarelto marketed details and API Manufacturers
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationMarken For more information visit: www.marken.com
ceocfointerviews.com All rights reserved! Issue: January 18, 2016 The Most Powerful Name in Corporate News Global Supply Chain Service Provider to the Pharmaceutical and Healthcare Industry We are tracking
More informationDrug Pooling in Clinical Trial Supply Chain
Drug Pooling in Clinical Trial Supply Chain Drug pooling in clinical trial is a process where common IMPs or Non-IMPs are pooled together for similar protocols running at each site followed by pooled distribution
More informationProviding Trusted and Innovative Solutions t o the Life Science Communities
Providing Trusted and Innovative Solutions t o the Life Science Communities Eurogentec Eurogentec is a leading supplier of trusted and innovative reagents, kits, specialty products and custom research/development
More informationAdocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
More informationCredit Suisse Healthcare Conference
Credit Suisse Healthcare Conference November 14, 2013 Safe Harbor Statement 2 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationIron Deficiency Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment,
Brochure More information from http://www.researchandmarkets.com/reports/2980507/ Iron Deficiency Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment Description: Iron Deficiency
More informationThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone Individuals, Families, States, Taxpayers All Face Higher Costs Due to Rising Drug Prices Prescription drugs are one of the major drivers
More informationBreakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014
Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00
More informationMARKET FOCUS REPORT THE VALUE OF MOBILE AND SOCIAL FOR CRM
Document M13 MARKET FOCUS REPORT THE VALUE OF MOBILE AND SOCIAL FOR CRM THE BOTTOM LINE Adding mobile access and social collaboration to CRM delivers significant benefits. In a survey of CRM decision makers,
More informationVOLVO INDIA PVT. LTD.
VOLVO INDIA PVT. LTD. Background Volvo is a Latin word that means I roll and it has become synonymous with high-quality trucks and buses in several countries. Established in Sweden in 1927, Volvo has today
More informationChina has become the world s factory, second only to the USA in terms of CO 2 emissions among major industrial countries.
PEPTIDES & PROTEINS When it comes to peptide manufacturing, we are all Chinese Jim Hampton, executive vice-president of business development at AmbioPharm, describes sourcing trends for raw materials,
More informationREGULATORY OVERVIEW DISTRIBUTION OF PHARMACEUTICAL PRODUCTS
REGULATORY FRAMEWORK Our products are subject to regulatory controls governing pharmaceutical products and medical appliances and equipment. Thus we are subject to regulation and oversight by different
More informationThe wool fibre is capable of producing vastly superior product by segregating fleeces from sheep to garment, but to do so is expensive.
CASE STUDY 2 : WOOL SUPPLY CHAIN 1 Synopsis This is a story about a joint venture arrangement in a wool supply chain, from Australian woolgrower to European weaver. The arrangement operated from 1994 until
More informationDear Business Development or Corporate Alliance Director/Manager,
Korea Drug Research Association(KDRA) and Korea Health Industry Development Institute(KHIDI) cordially request the potential global outsourcing partners(cros, CMOs, CSOs & Consulting Firms) having contract
More informationThe Historical Evolution of China s Drug Regulatory System
The Historical Haona Li 1, He Sun 1,Frances J Richmond 23 1 School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China 2 School of Pharmacy, University of Southern California,
More informationChronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
Brochure More information from http://www.researchandmarkets.com/reports/3533727/ Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 Description: SUMMARY The
More informationFlamel Technologies Announces Second Quarter Results of Fiscal Year 2015
Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015 Product revenue guidance for 2015 of $170-$185 million reaffirmed Conference call with management to take place at 10:00 am ET on
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationImplication of China 2012 NEDL. Presented by: Li Xingwei Yong Hueyling
Implication of China 2012 NEDL to MNC pharma players Presented by: Li Xingwei Yong Hueyling Content Brief introduction of China NEDL policy China hospital system & MNCs Business Focus Influence of 2012
More informationMedium-term Business Plan
Mitsubishi UFJ Financial Group, Inc. Medium-term Business Plan Tokyo, May 15, 2015 --- Mitsubishi UFJ Financial Group, Inc. (MUFG) announced today that it has formulated its medium-term business plan for
More informationSimulation-based Optimization Approach to Clinical Trial Supply Chain Management
20 th European Symposium on Computer Aided Process Engineering ESCAPE20 S. Pierucci and G. Buzzi Ferraris (Editors) 2010 Elsevier B.V. All rights reserved. Simulation-based Optimization Approach to Clinical
More informationOVERSEAS REGULATORY ANNOUNCEMENT
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
More informationAnnual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
More informationIndian Agrochemical Industry
Indian Agrochemical Industry Introduction. India is the fourth largest producer of agrochemicals globally, after United States, Japan and China. The agrochemicals industry is a significant industry for
More informationWORLD. Geographic Trend Report for GMAT Examinees
2011 WORLD Geographic Trend Report for GMAT Examinees WORLD Geographic Trend Report for GMAT Examinees The World Geographic Trend Report for GMAT Examinees identifies mobility trends among GMAT examinees
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More information2.2. DPP is a provider of chemical- and biotechnologies
2.1 2.2 DSM Pharmaceutical Products (DPP) together with DSM Anti-Infectives are the constituent parts of DSM s Pharma cluster. Net sales in 2006, for the Pharma cluster was 1 billion, 60% of this being
More informationAn Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore A CanBiotech Report CanBiotech, 2007 1 An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight
More informationFDA Center for Drug Evaluation and Research (CDER)
FDA Center for Drug Evaluation and Research (CDER) Strategic Plan 2013-2017 Table of Contents Section Page I. Introduction.. 3 II. CDER Mission and Basic Business Model.. 3 III. Stakeholder Considerations
More informationComparisons of Retail Prices of Generic Prescription Drugs in Canada vs. United States: A Comprehensive Study
Comparisons of Retail Prices of Generic Prescription Drugs in Canada vs. United States: A Comprehensive Study A Report Prepared for the Canadian Generic Pharmaceutical Association By Joseph R. D Cruz Murray
More informationMatthew Emmens CEO Shire plc
Goldman Sachs 28 th Annual Global Healthcare Conference June 13, 2007 Matthew Emmens CEO Shire plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationAn Industry White Paper
Driving Continuity and Collaboration from Lab Floor to Plant Floor to Top Floor An Industry White Paper Who is AspenTech? AspenTech is a global company founded in 1981 with more than 1,300 employees in
More informationThe Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts
More informationDevelopmental Patterns of Offshore IT Service Companies
DEVELOPMENTAL PATTERNS OF OFFSHORE IT SERVICE COMPANIES: APPLICATION OF INFORMATION TECHNOLOGY VALUE CHAIN George Mangalaraj, College of Business, University of Texas at Arlington, Arlington, TX 76019
More informationINDUSTRY OVERVIEW SOURCE OF INFORMATION. Report prepared by Euromonitor
The information that appears in this Industry Overview has been prepared by Euromonitor International Limited and reflects estimates of market conditions based on publicly available sources and trade opinion
More informationTHE CPA AUSTRALIA ASIA-PACIFIC SMALL BUSINESS SURVEY 2015
THE CPA AUSTRALIA ASIA-PACIFIC SMALL BUSINESS SURVEY GENERAL REPORT FOR AUSTRALIA, CHINA, HONG KONG, INDONESIA, MALAYSIA, NEW ZEALAND, SINGAPORE AND VIETNAM 2 THE CPA AUSTRALIA ASIA-PACIFIC SMALL BUSINESS
More informationFDA USER FEES 2012: HOW INNOVATION HELPS PATIENTS
SUMMARY OF THE GENERIC PHARMACEUTICAL ASSOCIATION TESTIMONY BEFORE THE ENERGY AND COMMERCE SUBCOMMITTEE ON HEALTH UNITED STATES HOUSE OF REPRESENTATIVES APRIL 18, 2012 FDA USER FEES 2012: HOW INNOVATION
More informationPharmaceutical development is an expensive, time
Exclusivity Strategies in the United States and European Union by Carolyne Hathaway, John Manthei and Cassie Scherer Pharmaceutical development is an expensive, time consuming and uncertain process that
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationSTRATEGY UPDATE 2 MARCH 2016
STRATEGY UPDATE 2 MARCH 2016 Portfolio Focus on Attractive Growth and Margin Opportunities André Lacroix, CEO Intertek Group plc, is today announcing a strategic update outlining the Group s plan to deliver
More informationStrategic Benefits of an Online Clinical Data Repository
Strategic Benefits of an Online Clinical Data Repository 5625 Dillard Drive Suite 205 Cary, NC 27518 www.pharsight.com Strategic Benefits of an Online Clinical Data Repository Contents Introduction 2 The
More informationSmruthi Organics Limited BSE Scrip Code: 590046
Smruthi Organics Limited BSE Scrip Code: 590046 Pharmaceuticals September 21, 2012 Equity Statistics Current Market Price Rs. 218.1 52 Week High / Low Rs. 273.9 / 155 Market Capitalisation Rs. crores 83.2
More informationAnalysis of Survey Results
Analysis of Survey Results 调 查 结 果 分 析 The American Chamber of Commerce in Shanghai 上 海 美 国 商 会 -2011 China business report Analysis of survey results Survey Overview This year s survey was conducted online
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationGLOBAL TREND REPORT MARKETING 2015 OUTLOOK
GLOBAL TREND REPORT MARKETING 015 2015 OUTLOOK A HIGHLY POSITIVE OUTLOOK FOR MARKETING PROFESSIONALS The Marketing discipline has been evolving rapidly over the past few years. The emphasis on digital
More informationLogistics. Drug Pooling in the Clinical Trial Supply Chain
Drug Pooling in the Clinical Trial Supply Chain Abstract Global clinical trials require efficient and robust supply chain which can bring more transparency and can introduce risk mitigation strategies.
More informationOveractive Bladder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
Brochure More information from http://www.researchandmarkets.com/reports/3533933/ Overactive Bladder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 Description: SUMMARY The Report,
More informationSmall Business Assistance
Small Business Assistance Products Ronald.Wilson@fda.hhs.gov Financial Assistance and Incentives for Research and Development of New Drug/Biologic Ron Wilson, Director of Small Business Assistance Center
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationPharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success
Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals
More informationDr. Reddy s Q3 and 9M FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationRepligen Reports Third Quarter 2015 Financial Results
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2015 Financial Results - Product Sales Increase 31% to $19.8 Million - - Conference
More informationInnovation and growth in China and India
Innovation and growth in China and India Professor Sunil Mani Planning Commission Chair Professor in Development Economics Centre for Development Studies Trivandrum, Kerala, India Email : mani@cds.ac.in
More information5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned
PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationQualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
More informationBiopharm Roundtable. 1. What, in your opinion, is currently the single largest trend with respect to biopharmaceutical outsourcing and manufacture?
BIOPHARM ROUNDTABLE Biopharm Roundtable Morrey Atkinson Vice President, R&D Cook Pharmica Peter Soelkner Managing Director Vetter Pharma-Fertigung GmbH & Co. KG Johannes Reiter Cooperations Manager Sandoz
More information